ReviewJournal of medical virology2020
Clinical trial analysis of 2019-nCoV therapy registered in China.
Review in Journal of medical virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Exploration of severe Covid-19 associated risk factor in China: Meta-analysis of current evidence.International journal of clinical practice · 2021Pooled it
- The possible of immunotherapy for COVID-19: A systematic review.International immunopharmacology · 2020Pooled it
- Research Collaboration and Outcome Measures of Interventional Clinical Trial Protocols for COVID-19 in China.Frontiers in public health · 2020Pooled it
- [Intensive care during the 2019-coronavirus epidemic].Medicina intensivaPooled it
- Trial
- Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.Med (New York, N.Y.) · 2020Trial
- Review
- Back to the Future: Immune Protection or Enhancement of Future Coronaviruses.Microorganisms · 2024Review
- Disparities in COVID-19 clinical studies from high-income and low-and middle-income countries.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Article
- Nanostructures for prevention, diagnosis, and treatment of viral respiratory infections: from influenza virus to SARS-CoV-2 variants.Journal of nanobiotechnology · 2023Review
- Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection.Signal transduction and targeted therapy · 2023Review
- SARS-CoV-2 infection and immune responses.AIMS microbiology · 2023Review
- Antiviral Potential of Plants against COVID-19 during Outbreaks-An Update.International journal of molecular sciences · 2022Review
- Antiviral and Anti-Inflammatory Plant-Derived Bioactive Compounds and Their Potential Use in the Treatment of COVID-19-Related Pathologies.Journal of xenobiotics · 2022Review
- Epigenetic regulation of autophagy in coronavirus disease 2019 (COVID-19).Biochemistry and biophysics reports · 2022Article
- Article
- Safety and Efficacy of Antiviral Drugs for the Treatment of COVID-19: A Systematic Review.Infection and drug resistance · 2022Review
- Article
- Convalescent plasma bank facility location-allocation problem for COVID-19.Transportation research. Part E, Logistics and transportation review · 2021Article
- Current treatment strategies for COVID‑19 (Review).Molecular medicine reports · 2021Review
31 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than 100 clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine, and other Western drugs, while Chinese medicine research accounted for half of the studies. Most of the trials were initiated by investigators and the study period would last for 1 to 11 months. The primary endpoints included symptom improvement and virus nucleic acid turning negative, but the optimal endpoint has not been determined. Although the final results of studies will take a long time to complete, the interim research data may provide some help for the current urgent demand for drug treatment. Compared with that of during SARS period in 2003, China has the stronger capability to carry out clinical trials of new drugs in emergency period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.